ORENCIA Drug Profile

Summary for Tradename: ORENCIA

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ORENCIA

Recent Clinical Trials for ORENCIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kashiv BioSciences, LLC	PHASE1
Dr. Reddy's Laboratories Limited	Phase 1
Idelberto Badell	Phase 1

See all ORENCIA clinical trials

Pharmacology for ORENCIA

Physiological Effect	Decreased Cytokine Activity
Established Pharmacologic Class	Selective T Cell Costimulation Modulator
Chemical Structure	Recombinant Fusion Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ORENCIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ORENCIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,450,361	2033-05-31	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	5,844,095	2015-12-01	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	5,851,795	2015-12-22	DrugPatentWatch analysis and company disclosures
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	6,685,941	2021-02-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ORENCIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,016,338	2036-12-20	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,023,894	2035-08-21	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,052,345	2031-10-14	Patent claims search
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	10,088,479	2035-01-13	Patent claims search

International Patents for ORENCIA

Country	Patent Number	Estimated Expiration
Taiwan	201008596
Slovenia	2253644
Taiwan	I398520
European Patent Office	2253644

Supplementary Protection Certificates for ORENCIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2008014,C1372696	Lithuania		PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007-05-21, EU/1/07/389/002, 2007-05-21, EU/1/07/389/003 20070521
PA2008014	Lithuania		PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007 05 21, EU/1/07/389/002, 2007 05 21, EU/1/07/389/003 20070521
C 2009 001	Romania		PRODUCT NAME: ABATACEPT PROTEINADE FUZIUNE 1-25-ONCOSTATIN M(PRECURSOR UMAN) CU PROTEINA DE FUZIUNE AANTIGENULUI UMAN CTLA-4 CU FRAGMENTUL GREUAL CATENEI DE IMUNOGLOBULINA G1 UMANA - ABATACEPT; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/389/001, RO EU/1/07/389/002, RO EU/1/07/389/003; DATE OF NATIONAL AUTHORISATION: 20070521; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/07/389/001, EMEA EU/1/07/389/002, EMEA EU/1/07/389/003; DATE OF FIRST AUTHORISATION IN EEA: 20070521

ORENCIA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What Is ORENCIA's Current Market Position?

ORENCIA (abatacept), a selective T-cell costimulation modulator, is marketed by Bristol Myers Squibb. It is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and polyarticular course juvenile idiopathic arthritis (pcJIA).

Indication	Status	Age Group
Rheumatoid Arthritis (Moderate to Severe)	Approved	Adult
Psoriatic Arthritis	Approved	Adult
Polyarticular Course Juvenile Idiopathic Arthritis	Approved	Pediatric

As of Q4 2023, ORENCIA's primary competitive landscape in RA includes other biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Key competitors include TNF inhibitors (e.g., adalimumab, etanercept, infliximab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib), and other biologics like rituximab and tocilizumab. In PsA, the competitive set is similar, with TNF inhibitors and IL-17 inhibitors being prominent. For pcJIA, ORENCIA competes with other biologics and methotrexate.

The drug is available in intravenous (IV) and subcutaneous (SC) formulations. The SC formulation, approved in 2007, offers a convenient, at-home administration option compared to the IV formulation's requirement for clinic visits, contributing to its market uptake and patient preference for long-term management.

What Are ORENCIA's Key Financial Performance Indicators?

Bristol Myers Squibb reported net sales for ORENCIA. The following table details historical net sales:

Year	Net Sales (USD Billions)
2021	2.97
2022	2.99
2023	2.93

Source: Bristol Myers Squibb SEC Filings

The sales trajectory indicates a period of relative stability. While 2023 saw a slight decline of 2.0% compared to 2022, this follows a period of marginal growth from 2021 to 2022 (0.7%). This performance suggests a mature market position where sales are influenced by patient adherence, physician prescribing patterns, and competitive pressures rather than rapid expansion.

What is the Patent Expiration Status for ORENCIA?

ORENCIA's primary composition of matter patent has expired in major markets. The U.S. patent for abatacept (ORENCIA) expired in 2023. European patent expiries have also occurred. The expiration of these core patents opens the door for the development and approval of biosimilars.

The U.S. Food and Drug Administration (FDA) has a framework for biosimilar approval. The pathway involves demonstrating high similarity in terms of physicochemical properties, biological activity, and clinical safety and efficacy between the biosimilar and the reference product (ORENCIA).

Several biosimilars for abatacept have been approved or are in development. For instance, Samsung Bioepis received FDA approval for its biosimilar candidate to ORENCIA in July 2023. Other companies, including Pfizer and Celltrion Healthcare, have also developed or are developing abatacept biosimilars.

The introduction of biosimilars is expected to impact ORENCIA's market share and pricing. Biosimilars typically enter the market at a lower price point than the originator biologic, driving uptake through cost savings for payers and healthcare systems.

What is the Impact of Biosimilar Entry on ORENCIA's Market Share and Revenue?

The U.S. market saw the first FDA approval of an ORENCIA biosimilar in July 2023. While initial market penetration of biosimilars can be gradual, historical data from other biologics suggest that biosimilar entry can lead to a significant decline in originator sales over time.

For example, following the entry of adalimumab biosimilars in Europe, Humira (adalimumab) experienced substantial revenue declines in those markets. The competitive landscape in RA and PsA is crowded, with many treatment options available. This means that switching to biosimilars may be more readily accepted by physicians and patients, especially when driven by cost considerations.

The full impact on ORENCIA's revenue is anticipated to unfold over the next several years as more biosimilars gain market access and achieve broader clinical adoption. The rate of uptake will depend on factors such as pricing strategies of biosimilar manufacturers, formulary placement by payers, physician education and confidence, and patient acceptance.

Bristol Myers Squibb's strategy to mitigate biosimilar impact typically involves leveraging its existing patient base, focusing on ORENCIA's established clinical profile, and potentially exploring lifecycle management strategies, although specific details for ORENCIA's post-patent exclusivity phase are proprietary.

What is the Future Outlook for ORENCIA and its Biosimilars?

The future outlook for ORENCIA involves a bifurcated market. The originator product will face increasing competition from an expanding pipeline of biosimilars. The market share of ORENCIA will likely contract as biosimilar versions gain traction, driven by their cost advantage.

Factor	Impact on ORENCIA (Originator)	Impact on Biosimilars
Pricing	Downward pressure	Competitive advantage
Market Share	Declining	Increasing
Revenue	Declining	Increasing
Physician Adoption	Potential decrease	Increasing
Payer Reimbursement	Increased scrutiny, potential restrictions	Favorable

The total market for abatacept, however, may see overall growth due to increased accessibility and affordability driven by biosimilars, potentially leading to higher patient utilization in indications like RA and PsA. The efficacy and safety profiles of approved biosimilars are required to be highly similar to ORENCIA, suggesting comparable therapeutic outcomes for patients.

Bristol Myers Squibb's revenue from ORENCIA is projected to decrease significantly in the coming years. The company's strategic focus will likely shift towards its newer growth drivers and pipeline assets. For biosimilar manufacturers, the U.S. market represents a substantial opportunity to capture market share in a therapeutic area with established demand.

The long-term competitive dynamic will be shaped by the number of biosimilars entering the market, their pricing strategies, and the evolving reimbursement policies of major healthcare payers. Regulatory clarity and continued post-market surveillance will also play a role in the sustained adoption of biosimilars.

Key Takeaways

• ORENCIA (abatacept) is a mature biologic drug with stable, albeit slightly declining, net sales in recent years, facing competition in RA, PsA, and pcJIA.
• The U.S. composition of matter patent for ORENCIA has expired, leading to the approval and imminent market entry of biosimilars.
• The introduction of biosimilars is expected to exert significant downward pressure on ORENCIA's pricing and market share, with a projected revenue decline.
• The overall market for abatacept therapies may expand due to increased affordability and accessibility brought about by biosimilar competition, benefiting biosimilar manufacturers.

Frequently Asked Questions

When was ORENCIA first approved?

ORENCIA was first approved by the U.S. Food and Drug Administration (FDA) for rheumatoid arthritis in adults in 2005.

What are the main indications for ORENCIA?

The main indications for ORENCIA are moderate to severe active rheumatoid arthritis, psoriatic arthritis, and polyarticular course juvenile idiopathic arthritis.

What is the difference between ORENCIA and its biosimilars?

Biosimilars are highly similar to the reference product (ORENCIA) in terms of physicochemical properties, biological activity, and clinical safety and efficacy. They are not identical, but the differences are expected to be without clinically meaningful impact on safety or effectiveness.

How does biosimilar pricing typically affect originator drug sales?

Biosimilar pricing is typically set lower than the originator biologic, leading to increased price competition and a subsequent decline in the originator's market share and revenue as payers and providers adopt the more cost-effective option.

What is Bristol Myers Squibb's strategy regarding ORENCIA's patent expiration?

While specific strategies are proprietary, companies typically focus on leveraging established brand loyalty, emphasizing clinical benefits, and reallocating resources to newer pipeline assets to manage the impact of biosimilar competition.